Weld Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Weld Capital Management’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-20,073	Closed	-$869K	–	620
2020 Q4	$869K	Buy	+20,073	New	+$990K	0.34%	83
2020 Q3	–	Sell	-5,859	Closed	-$370K	–	699
2020 Q2	$370K	Buy	+5,859	New	+$402K	0.15%	223
2019 Q3	–	Sell	-4,629	Closed	-$243K	–	1069
2019 Q2	$243K	Buy	+4,629	New	+$266K	0.04%	602

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Weld Capital Management's GBT Position: Q1 2021 in Review

Weld Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 20,073 shares — an estimated $869K sold.

Weld Capital Management first reported a position in GBT in Q2 2019 and held it in 3 quarters. The position peaked at $869K in Q4 2020. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

Weld Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Weld Capital Management sold 20,073 Global Blood Therapeutics, Inc. shares in Q1 2021, an estimated $869K.
Weld Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 3 quarters.
Weld Capital Management's Global Blood Therapeutics, Inc. position peaked at $869K in Q4 2020.
214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on Weld Capital Management's 13F filing for Q1 2021, filed 17 May 2021.